Friday, July 10, 2026

pharma · Esophageal Cancer · Esophageal Squamous Cell Carcinoma

Shanghai SIMR Biotech

Shanghai SIMR Biotech clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Shanghai, CN HQ
2014 Founded
23 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Shanghai, CN
Founded
2014
Employees
23
Programs
3
Drugs
14
Patents
0
Intelligence · Clinical Programs

Shanghai SIMR Biotech projects

3 ClinicalTrials.gov programs sponsored by Shanghai SIMR Biotech.

Shanghai SIMR Biotech has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. PD-1inhibitor

    Shanghai Chest Hospital

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial
  2. SCHLC007

    Shanghai Chest Hospital

    NSCLC

    phase 2 small molecule active

    1 trial
  3. neoadjuvant anti-PD-1

    Shanghai Chest Hospital

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Shanghai SIMR Biotech have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.